- In the first quarter of 2026, Zevra Therapeutics reported sales of US$36.22 million, net income of US$37.89 million, and a swing to positive earnings per share, supported by a US$43.3 million gain from selling its SDX portfolio and retiring US$63.1 million of term debt.
- At the same time, Zevra sharpened its rare disease focus with early MyPlifer traction in Niemann-Pick disease type C, progress on celiprolol for vascular Ehlers-Danlos syndrome, and a strong cash position of US$236.8 million, while FMR LLC disclosed a 5.5% ownership stake.
- We will now examine how this combination of profitable Q1 results and a debt-free balance sheet may reshape Zevra’s investment narrative.
The latest GPUs need a type of rare earth metal called Terbium and there are only 33 companies in the world exploring or producing it. Find the list for free.
Zevra Therapeutics Investment Narrative Recap
To own Zevra, you effectively have to believe its rare disease pivot around MIPLYFFA and celiprolol can offset OLPRUVA headwinds and a concentrated pipeline. The latest quarter delivered a one off boost to earnings and a debt free balance sheet, but the core near term catalyst still hinges on regulatory and commercial progress for MIPLYFFA in Europe, while the key risk remains the very small NPC patient pool and potential saturation in the US.
Against that backdrop, the most relevant update is Zevra’s early MyPlifer launch traction, with reach to roughly half of diagnosed US NPC patients and an ongoing EMA review. This ties the current earnings jump back to the fundamental question of how far MIPLYFFA adoption and access can go, both in the US and abroad, before market size and reimbursement hurdles start to bite.
Yet beneath the strong Q1 print, investors should still be mindful of how quickly an ultra rare market like NPC can approach saturation and...
Read the full narrative on Zevra Therapeutics (it's free!)
Zevra Therapeutics' narrative projects $296.5 million revenue and $151.4 million earnings by 2028. This requires 68.5% yearly revenue growth and a $155.3 million earnings increase from $-3.9 million today.
Uncover how Zevra Therapeutics' forecasts yield a $23.22 fair value, a 111% upside to its current price.
Exploring Other Perspectives
Before this Q1 news, the most optimistic analysts were modeling about US$470.1 million of 3 year revenue and US$319.9 million of earnings, a far more bullish view than consensus, so you should weigh how that upside case around rapid NPC uptake and European expansion might need to be revisited in light of Zevra’s smaller patient pool and concentrated rare disease focus.
Explore 10 other fair value estimates on Zevra Therapeutics - why the stock might be worth over 6x more than the current price!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Zevra Therapeutics research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Zevra Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zevra Therapeutics' overall financial health at a glance.
Seeking Other Investments?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- Capitalize on the AI infrastructure supercycle with our selection of the 40 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com